Manulife has announced an exclusive partnership with Guardant Health, a precision oncology company, to introduce the Shield Multi-Cancer Detection (MCD) test to its customers in Hong Kong, Singapore, and the Philippines. This marks the first time the innovative blood-based screening solution will be available in Asia, offering a significant advancement in proactive health management.
The Shield MCD test, which screens for 10 common cancers with high mortality rates in Asia, requires only a blood draw and has received Breakthrough Device Designation from the US Food and Drug Administration in June 2025. This partnership underscores Manulife’s commitment to providing innovative health solutions that address unmet needs.
Steve Finch, President and CEO of Manulife Asia, stated, “By being the first insurer in Asia to offer the Shield MCD test, we’re empowering our customers with a credible and valued service that encourages proactive health management.” This collaboration builds on the existing relationship between Manulife and Guardant Health in Singapore, where they offer the Guardant360 liquid biopsy test for advanced solid tumours.
The introduction of the Shield MCD test is expected to significantly impact cancer detection and management in the region, potentially improving health outcomes for many. As cancer remains a leading cause of death in Asia, this partnership aims to enhance early detection and treatment options for patients.
